Japan · Delayed Price · Currency is JPY Modalis Therapeutics Company Description
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders.
It is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology that enables to control gene expressions through modulating the switch (epigenetics of a specific locus.
The company has a. joint research agreement with JCR Pharmaceuticals Co., Ltd. to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target; and a strategic collaboration with SOLVE FSHD to develop an innovative therapy for facioscapulohumeral muscular dystrophy, a debilitating muscular disorder.
The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019.
Modalis Therapeutics Corporation was founded in 2016 and is headquartered in Tokyo, Japan.
| Country | Japan |
| Founded | 2016 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Haruhiko Morita |
Contact Details
Address: Y’s Building Tokyo, 103-0026 Japan | |
| Website | modalistx.com |
Stock Details
| Ticker Symbol | 4883 |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| ISIN Number | JP3922600006 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Haruhiko Morita | Chief Executive Officer |